Related Experiment Video

Updated: Jun 16, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

New agents in advanced non-small-cell lung cancer treatment

Serena Ricciardi1, Filippo de Marinis

  • 1Thoracic-Oncology Unit 1st, Lung Diseases Department, San Camillo-Forlanini High Specialization Hospitals, Rome, Italy. sricciardi@interfree.it

Oncology
|February 5, 2010
PubMed

Insights

New targeted therapies offer a promising treatment paradigm for lung cancer, often in combination with standard chemotherapy. Further research into adverse events associated with these novel lung cancer treatments is essential.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Lung cancer remains the leading cause of cancer mortality globally.
  • Targeted therapies, tailored to molecular and biological profiles, represent a significant advancement in lung cancer treatment.
  • Platinum-based combination therapy is the current standard for advanced non-small-cell lung cancer (NSCLC).

Purpose of the Study:

  • To review emerging targeted therapies for non-small-cell lung cancer (NSCLC).
  • To discuss the potential role of novel agents in combination with standard treatments.
  • To highlight the need for further investigation into the adverse events of targeted lung cancer therapies.

Main Methods:

  • Review of ongoing phase I and II clinical trials for NSCLC.
  • Analysis of recently registered targeted drugs including sorafenib, sunitinib, mTOR inhibitors, and ASA404.
  • Evaluation of the potential for combination strategies in NSCLC treatment.

Main Results:

  • Several new targeted drugs are under investigation for NSCLC.
  • Combination therapy with novel agents and standard cytotoxic or targeted agents is a likely optimal approach.
  • Increased patient numbers receiving targeted therapy necessitate urgent investigation of adverse events.

Conclusions:

  • Targeted therapies are revolutionizing NSCLC treatment paradigms.
  • Combination strategies hold significant promise for improving patient outcomes in advanced NSCLC.
  • Comprehensive understanding and management of adverse events are critical for the successful integration of targeted therapies.

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...